Next Article in Journal
Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus
Previous Article in Journal
Development of Phosphorothioate DNA and DNA Thioaptamers
Previous Article in Special Issue
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
Open AccessReview

Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein

Department of Experimental Therapeutics, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Biomedicines 2017, 5(3), 42;
Received: 24 May 2017 / Revised: 7 July 2017 / Accepted: 11 July 2017 / Published: 17 July 2017
(This article belongs to the Special Issue Targeted Human Cytolytic Fusion Proteins)
Angiogenesis is a critical process in numerous diseases, and intervention in neovascularization has therapeutic value in several disease settings, including ocular diseases, arthritis, and in tumor progression and metastatic spread. Various vascular targeting agents have been developed, including those that inhibit growth factor receptor tyrosine kinases, blocking antibodies that interfere with receptor signal transduction, and strategies that trap growth factor ligands. Limited anti-tumor efficacy studies have suggested that the targeted delivery of the human pro-apoptotic molecule Granzyme B to tumor cells has significant potential for cancer treatment. Here, we review biological vascular targeting agents, and describe a unique vascular targeting agent composed of Granzyme B and the VEGF receptor ligand VEGF121. The fusion protein GrB/VEGF121 demonstrates cytotoxicity at nanomolar or sub-nanomolar levels, excellent pharmacokinetic and efficacy profiles, and has significant therapeutic potential targeting tumor vasculature. View Full-Text
Keywords: Granzyme B; fusion protein; angiogenesis; vascular targeting Granzyme B; fusion protein; angiogenesis; vascular targeting
Show Figures

Graphical abstract

MDPI and ACS Style

Mohamedali, K.A.; Rosenblum, M.G. Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein. Biomedicines 2017, 5, 42.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop